HilleVax and XOMA Royalty Announce Merger Agreement
BOSTON and EMERYVILLE, Calif. – In an exciting development in the biopharmaceutical landscape, HilleVax, Inc. (NASDAQ: HLVX) has confirmed its plans to be acquired by XOMA Royalty Corporation (NASDAQ: XOMA). This strategic decision comes as both companies continue to innovate in the realm of biotechnology.
Details of the Merger Agreement
The definitive merger agreement revealed that HilleVax shareholders will receive $1.95 in cash for each share, alongside a non-transferable contingent value right (CVR). This right allows stockholders the opportunity to benefit from future developments of HilleVax's projects and assets.
As part of the acquisition, HilleVax's existing cash reserves beyond $102.95 million will also be up for potential disbursement. Moreover, a significant portion of savings anticipated from negotiations on office lease obligations in Boston is included in the agreement, providing further incentive for both current and future stakeholders.
Strategic Review and Approval
HilleVax’s Board of Directors has made a unanimous decision, supported by extensive consultations with legal and financial experts, indicating that the merger with XOMA Royalty serves the best interests of all HilleVax stockholders. This commitment was reinforced by the company's intent to strengthen its market position within the industry.
According to the agreement, XOMA Royalty will initiate a tender offer by August 18, which will aim to acquire all shares. There are, however, specific conditions attached to this offer. For instance, XOMA Royalty requires a majority of shares to be tendered successfully for the tender offer to proceed to closure.
Anticipated Timeline of Ending the Merger
Pending the successful completion of the tender offer, the acquisition process is expected to be finalized in September, allowing both companies to chart a unified path forward. Notably, approximately 22.9% of HilleVax's common stock is already committed to support the merger, reflecting confidence in the future direction of the organization under XOMA's umbrella.
Expert Guidance
Leerink Partners has been selected as HilleVax’s exclusive financial advisor. They are joined by Latham & Watkins LLP for legal advice to HilleVax. On the other side, XOMA Royalty has engaged Gibson, Dunn & Crutcher LLP to facilitate their legal needs during the merger process.
About HilleVax
HilleVax stands out in the clinical-stage biopharmaceutical domain, focusing on groundbreaking vaccine development. The merger is anticipated to bolster their resources and capabilities in this critical field of health.
Overview of XOMA Royalty Corporation
XOMA Royalty is a noted player in the biotechnology arena, specializing in acquiring economic rights tied to innovative therapeutic candidates. This acquisition aligns perfectly with their mission to promote human health through strategic investments in promising medical solutions.
Future Prospects and Opportunities
As both companies consolidate their operations, they are expected to leverage each other's strengths to enhance their influence in the biopharmaceutical market. The merger not only signifies a bold move for HilleVax but also strengthens XOMA Royalty's extensive portfolio of therapeutic assets.
Potential Investor Insights
These developments are noteworthy for investors keen on the biotechnology sector. Understanding the intricacies of this merger and its potential benefits to both parties can offer deeper insight into future market dynamics.
Frequently Asked Questions
What is the per-share cash offer for HilleVax stockholders?
HilleVax stockholders will receive $1.95 in cash per share at closing, plus a contingent value right.
What is a contingent value right?
A contingent value right (CVR) grants stockholders potential future payments based on certain conditions post-merger.
Who are the advisors involved in the merger?
Leerink Partners is the financial advisor for HilleVax, with legal support from Latham & Watkins LLP. XOMA Royalty is advised by Gibson, Dunn & Crutcher LLP.
When is the acquisition expected to close?
The acquisition is anticipated to be completed in September, following a successful tender offer.
What role does XOMA Royalty play in biotechnology?
XOMA Royalty focuses on acquiring financial rights to therapeutic candidates, helping biotech firms to accelerate their product development efforts.
